Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

Go back to Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

Regeneron (REGN) Tops Q4 EPS by 70c

February 8, 2018 6:32 AM EST

Regeneron (NASDAQ: REGN) reported Q4 EPS of $5.23, $0.70 better than the analyst estimate of $4.53. Revenue for the quarter came in at $1.58 billion versus the consensus estimate of $1.5 billion.

Fourth quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 14% to $975 million versus fourth... More